@article{f4631d3678654af5ad5328194d12ff92,
title = "Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study",
abstract = "Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.",
keywords = "Renal carcinoma, Suramin",
author = "Schroder, {Louis E.} and Danika Lew and Flanigan, {Robert C.} and Eisenberger, {Mario A.} and Seay, {Thomas E.} and Neel Hammond and Needles, {Burton M.} and Crawford, {E. David}",
note = "Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA45450, CA52386, CA35128, CA58416, CA35176, CA68183, CA46441, CA35178, CA22433, CA58415, CA35431, CA76462. ",
year = "2001",
doi = "10.1016/S1078-1439(00)00126-5",
language = "English (US)",
volume = "6",
pages = "145--148",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",
}